Literature DB >> 19711629

Is marketing the enemy of pharmaceutical innovation?

Kalman Applbaum1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19711629     DOI： 10.1353/hcr.0.0157

Source DB:  PubMed          Journal:  Hastings Cent Rep        ISSN： 0093-0334            Impact factor:   2.683


× No keyword cloud information.
  3 in total

Review 1.  The risks of risk aversion in drug regulation.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Daniel Brasseur; Alasdair Breckenridge; Hubert Leufkens; June Raine; Tomas Salmonson; Christian K Schneider; Guido Rasi
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

2.  Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.

Authors:  Jill A Fisher; Marci D Cottingham; Corey A Kalbaugh
Journal:  Soc Sci Med       Date:  2014-08-19       Impact factor: 4.634

3.  The earlier the better: Alzheimer's prevention, early detection, and the quest for pharmacological interventions.

Authors:  Annette Leibing
Journal:  Cult Med Psychiatry       Date:  2014-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.